BioNTech (NASDAQ:BNTX) Trading Down 3.3%

BioNTech SE (NASDAQ:BNTX – Get Rating) fell 3.3% on Friday . The company traded as low as $104.85 and last traded at $105.12. 264,074 shares were traded during trading, a decline of 62% from the average session volume of 699,929 shares. The stock had previously closed at $108.73.

Analyst Ratings Changes

BNTX has been the topic of a number of recent research reports. The Goldman Sachs Group set a $140.00 price objective on BioNTech and gave the company a “neutral” rating in a research note on Tuesday, March 28th. Bank of America reduced their price objective on BioNTech from $239.00 to $194.00 and set a “buy” rating on the stock in a research note on Monday, March 27th. HC Wainwright reduced their price objective on BioNTech from $210.00 to $198.00 in a research note on Tuesday. TheStreet cut BioNTech from a “b-” rating to a “c+” rating in a research note on Monday, March 27th. Finally, Berenberg Bank set a $260.00 target price on BioNTech in a research note on Tuesday, March 28th. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $172.20.

BioNTech Stock Down 2.5 %

The company’s fifty day moving average price is $118.08 and its 200-day moving average price is $139.34. The stock has a market capitalization of $25.79 billion, a PE ratio of 4.18 and a beta of 0.21. The company has a quick ratio of 12.68, a current ratio of 12.95 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX – Get Rating) last released its earnings results on Monday, May 8th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $1.87. BioNTech had a net margin of 51.03% and a return on equity of 32.52%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the business earned $15.98 earnings per share. The business’s revenue was down 80.0% on a year-over-year basis. Analysts forecast that BioNTech SE will post 5.32 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Baillie Gifford & Co. lifted its position in BioNTech by 6.5% in the 4th quarter. Baillie Gifford & Co. now owns 7,718,123 shares of the company’s stock valued at $1,159,416,000 after acquiring an additional 473,051 shares in the last quarter. Temasek Holdings Private Ltd lifted its position in BioNTech by 714.3% in the 3rd quarter. Temasek Holdings Private Ltd now owns 4,378,022 shares of the company’s stock valued at $590,508,000 after acquiring an additional 3,840,388 shares in the last quarter. Flossbach Von Storch AG lifted its position in BioNTech by 4.6% in the 1st quarter. Flossbach Von Storch AG now owns 3,432,334 shares of the company’s stock valued at $427,566,000 after acquiring an additional 149,611 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in BioNTech by 8.5% in the 1st quarter. Artisan Partners Limited Partnership now owns 2,610,858 shares of the company’s stock valued at $325,235,000 after acquiring an additional 204,158 shares in the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of BioNTech by 25.9% during the 1st quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock valued at $274,768,000 after buying an additional 331,101 shares during the period. 15.29% of the stock is owned by institutional investors.

BioNTech Company Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.